Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2023

Open Access 01-12-2023 | Neuroblastoma | Research

Prevention of STAT3-related pathway in SK-N-SH cells by natural product astaxanthin

Authors: Shao-Qian Sun, Feng-Xiang Du, Li-Hua Zhang, Hao-Shi, Fu-Ying Gu, Yu-Lin Deng, Yi-Zhi Ji

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Login to get access

Abstract

Purpose

Neuroblastoma (NB) is the most common solid malignancy in children. Despite current intensive treatment, the long-term event-free survival rate is less than 50% in these patients. Thus, patients with NB urgently need more valid treatment strategies. Previous research has shown that STAT3 may be an effective target in high-risk NB patients. However, there are no effective inhibitors in clinical evaluation with low toxicity and few side effects. Astaxanthin is a safe and natural anticancer product. In this study, we investigated whether astaxanthin could exert antitumor effects in the SK-N-SH neuroblastoma cancer cell line.

Method

MTT and colony formation assays were used to determine the effect of astaxanthin on the proliferation and colony formation of SK-N-SH cells. Flow cytometry assays were used to detect the apoptosis of SK-N-SH cells. The migration and invasion ability of SK-N-SH cells were detected by migration and invasion assays. Western blot and RT-PCR were used to detect the protein and mRNA levels. Animal experiments were carried out and cell apoptosis in tissues were assessed using a TUNEL assay.

Result

We confirmed that astaxanthin repressed proliferation, clone formation ability, migration and invasion and induced apoptosis in SK-N-SH cells through the STAT3 pathway. Furthermore, the highest inhibitory effect was observed when astaxanthin was combined with si-STAT3. The reason for this may be that the combination of astaxanthin and si-STAT3 can lower STAT3 expression further than astaxanthin or si-STAT3 alone.

Conclusion

Astaxanthin can exert anti-tumor effect on SK-N-SH cells. The inhibitory effect was the higher when astaxanthin was combined with si-STAT3.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Orr KE, McHugh K. The new international neuroblastoma response criteria. Pediatr Radiol. 2019;49(11):1433–40.CrossRefPubMed
4.
Gutierrez JC, et al. Markedly improving survival of neuroblastoma: a 30-year analysis of 1,646 patients. Pediatr Surg Int. 2007;23(7):637–46.CrossRefPubMed
5.
6.
7.
Wang HQ et al. STAT3 pathway in cancers: Past, present, and future MedComm (2020), 2022. 3(2): p. e124.
8.
Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18(2):254–67.CrossRefPubMed
9.
Zhang J, et al. Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer. Int J Clin Exp Pathol. 2011;4(4):356–62.PubMedPubMedCentral
10.
Jiang Y, et al. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, Metastasis and sorafenib resistance through STAT3 activation. J Cell Mol Med. 2021;25(3):1568–82.CrossRefPubMedPubMedCentral
11.
Eroglu M, et al. STAT3 expression is correlated with pathological stage in luminal subtypes of breast carcinoma. Bratisl Lek Listy. 2020;121(1):51–61.PubMed
12.
13.
Cirmi S, et al. Oleacein inhibits STAT3, activates the apoptotic machinery, and exerts anti-metastatic effects in the SH-SY5Y human neuroblastoma cells. Food Funct. 2020;11(4):3271–9.CrossRefPubMed
14.
15.
Odate S, et al. Inhibition of STAT3 with the Generation 2.5 antisense oligonucleotide, AZD9150, decreases Neuroblastoma Tumorigenicity and increases Chemosensitivity. Clin Cancer Res. 2017;23(7):1771–84.CrossRefPubMed
16.
Hadjidaniel MD, et al. Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. Oncotarget. 2017;8(53):91516–29.CrossRefPubMedPubMedCentral
17.
Agarwal S, et al. G-CSF promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer stem cell activation. Cancer Res. 2015;75(12):2566–79.CrossRefPubMedPubMedCentral
18.
Wang XH, et al. IGF1R facilitates epithelial-mesenchymal transition and cancer stem cell properties in neuroblastoma via the STAT3/AKT axis. Cancer Manag Res. 2019;11:5459–72.CrossRefPubMedPubMedCentral
19.
Okusaka T, et al. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol Res. 2015;45(13):1283–91.CrossRefPubMed
20.
21.
Lin L, et al. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human Multiple Myeloma cells. Int J Cancer. 2012;130(6):1459–69.CrossRefPubMed
22.
Ko HJ, Kim YJ. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer. Arch Pharm Res. 2016;39(11):1597–608.CrossRefPubMed
23.
Efsa Panel on Nutrition, N.F. Safety of astaxanthin for its use as a novel food in food supplements. EFSA J. 2020;18(2):e05993.
24.
Miki W, Yamaguchi K, Konosu S. Comparison of carotenoids in the ovaries of marine fish and Shellfish. Comp Biochem Physiol B. 1982;71(1):7–11.CrossRefPubMed
25.
Guerin M, Huntley ME, Olaizola M. Haematococcus astaxanthin: applications for human health and nutrition. Trends Biotechnol. 2003;21(5):210–6.CrossRefPubMed
26.
Lee J, Kim MH, Kim H. Anti-oxidant and anti-inflammatory effects of Astaxanthin on Gastrointestinal Diseases. Int J Mol Sci, 2022. 23(24).
27.
Si P, Zhu C. Biological and neurological activities of astaxanthin (review). Mol Med Rep, 2022. 26(4).
28.
Song XD, et al. Astaxanthin induces mitochondria-mediated apoptosis in rat hepatocellular carcinoma CBRH-7919 cells. Biol Pharm Bull. 2011;34(6):839–44.CrossRefPubMed
29.
Zhou Q, et al. A positive Feedback Loop of AKR1C3-Mediated activation of NF-kappaB and STAT3 facilitates proliferation and Metastasis in Hepatocellular Carcinoma. Cancer Res. 2021;81(5):1361–74.CrossRefPubMed
30.
Jin W. Role of JAK/STAT3 signaling in the regulation of Metastasis, the transition of Cancer Stem cells, and Chemoresistance of Cancer by epithelial-mesenchymal transition. Cells, 2020. 9(1).
31.
Song J, et al. Discovery of STAT3 inhibitors: recent advances and future perspectives. Curr Med Chem. 2023;30(16):1824–47.CrossRefPubMed
32.
Huang Q, et al. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: where are we and where should we go? Eur J Med Chem. 2020;187:111922.CrossRefPubMed
33.
Hong D, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in Lymphoma and Lung cancer. Sci Transl Med. 2015;7(314):314ra185.CrossRefPubMedPubMedCentral
34.
Modak S, Cheung NK. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev. 2010;36(4):307–17.CrossRefPubMed
35.
Liu WH, et al. Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid Tumor cells. Oncotarget. 2015;6(3):1750–68.CrossRefPubMedPubMedCentral
36.
Chen RJ, et al. Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human Bladder cancer cells. Toxicol Sci. 2010;115(1):118–30.CrossRefPubMed
37.
Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-hodgkin’s Lymphoma and Multiple Myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res. 2003;9(1):316–26.PubMed
38.
Wang Y, et al. Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and beta-catenin signaling pathways. Oncol Rep. 2011;26(5):1173–80.PubMed
39.
Duan Z, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant Ovarian cancer. Clin Cancer Res. 2006;12(17):5055–63.CrossRefPubMed
40.
Ishii Y, Waxman S, Germain D. Tamoxifen stimulates the growth of cyclin D1-overexpressing Breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res. 2008;68(3):852–60.CrossRefPubMed
41.
Redell MS, et al. Stat3 signaling in acute Myeloid Leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117(21):5701–9.CrossRefPubMedPubMedCentral
42.
Duan Z, et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant Ovarian cancer cells. Cancer Chemother Pharmacol. 2009;63(4):681–9.CrossRefPubMed
43.
Yang Z, et al. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget. 2015;6(7):5072–87.CrossRefPubMed
44.
45.
Davinelli S, Nielsen ME, Scapagnini G. Astaxanthin in skin health, repair, and Disease: a Comprehensive Review. Nutrients, 2018. 10(4).
Metadata
Title
Prevention of STAT3-related pathway in SK-N-SH cells by natural product astaxanthin
Authors
Shao-Qian Sun
Feng-Xiang Du
Li-Hua Zhang
Hao-Shi
Fu-Ying Gu
Yu-Lin Deng
Yi-Zhi Ji
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-04267-3

Other articles of this Issue 1/2023

BMC Complementary Medicine and Therapies 1/2023 Go to the issue

Study Protocol

Efficacy and safety of Yi Shen Fang granules in elderly people with MCI: study protocol for a multicentre, randomized, double-blind, parallel-group, controlled trial

Research

Nigella sativa powder for helicobacter pylori infected patients: a randomized, double-blinded, placebo-controlled clinical trial

Research

Prevalence and correlates of multimorbidity among patients attending AYUSH primary care settings in Delhi-National Capital Region, India

Research

Xiaoyaosan ameliorates depressive-like behavior and susceptibility to glucose intolerance in rat: involvement of LepR-STAT3/PI3K pathway in hypothalamic arcuate nucleus

Research

A model of purchase intention of complementary and alternative medicines: the role of social media influencers’ endorsements

Research

Potential of methacrylated acemannan for exerting antioxidant-, cell proliferation-, and cell migration-inducing activities in vitro